Skip to Main Content (Press Enter)

Logo UNINSUBRIA
  • ×
  • Home
  • Degrees
  • Courses
  • Jobs
  • People
  • Outputs
  • Organizations
  • Third Mission
  • Projects
  • Expertise & Skills

UNI-FIND
Logo UNINSUBRIA

|

UNI-FIND

uninsubria.it
  • ×
  • Home
  • Degrees
  • Courses
  • Jobs
  • People
  • Outputs
  • Organizations
  • Third Mission
  • Projects
  • Expertise & Skills
  1. Outputs

Management of hyperthyroidism due to Graves' disease: frequently asked questions and answers (if any)

Academic Article
Publication Date:
2016
abstract:
Graves’ disease is the most common cause of hyperthyroidism in iodine-replete areas. Although progress has been made in our understanding of the pathogenesis of the disease, no treatment targeting pathogenic mechanisms of the disease is presently available. Therapies for Graves’ hyperthyroidism are largely imperfect because they are bound to either a high rate of relapsing hyperthyroidism (antithyroid drugs) or lifelong hypothyroidism (radioiodine treatment or thyroidectomy). Aim of the present article is to offer a practical guidance to the reader by providing evidence-based answers to frequently asked questions in clinical practice.
Iris type:
Articolo su Rivista
Keywords:
Agranulocytosis; Alemtuzumab; Childhood; Graves’ disease; Graves’ orbitopathy; Hyperthyroidism; Methimazole; Pregnancy; Propylthiouracil; Radioiodine; Thionamides; Thyroidectomy
List of contributors:
Bartalena, Luigi; Chiovato, L.; Vitti, P.
Handle:
https://irinsubria.uninsubria.it/handle/11383/2061504
Published in:
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
Journal
  • Accessibility
  • Use of cookies

Powered by VIVO | Designed by Cineca | 26.6.0.0